Annexon Biosciences to Present at the TD Cowen 45th Annual Health Care Conference
Annexon Biosciences (Nasdaq: ANNX), a biopharmaceutical company focused on developing novel therapies for classical complement-mediated neuroinflammatory diseases, has announced its participation in the TD Cowen 45th Annual Health Care Conference.
The company's president and CEO, Douglas Love, will deliver a presentation on March 4, 2025, at 11:50 a.m. EST. Interested parties can access a live webcast of the presentation through the 'Events & Presentations' section on Annexon's Investors page. The presentation recording will remain available on the company's website for 30 days afterward.
Annexon Biosciences (Nasdaq: ANNX), un'azienda biofarmaceutica focalizzata sullo sviluppo di nuove terapie per le malattie neuroinfiammatorie mediate dal complemento classico, ha annunciato la sua partecipazione alla 45ª Conferenza Annuale sulla Salute di TD Cowen.
Il presidente e CEO dell'azienda, Douglas Love, presenterà il suo intervento il 4 marzo 2025, alle 11:50 EST. Le parti interessate possono accedere a una trasmissione in diretta della presentazione attraverso la sezione 'Eventi e Presentazioni' nella pagina Investitori di Annexon. La registrazione della presentazione rimarrà disponibile sul sito web dell'azienda per 30 giorni successivi.
Annexon Biosciences (Nasdaq: ANNX), una compañía biofarmacéutica centrada en el desarrollo de nuevas terapias para enfermedades neuroinflamatorias mediadas por el complemento clásico, ha anunciado su participación en la 45ª Conferencia Anual de Salud de TD Cowen.
El presidente y CEO de la compañía, Douglas Love, ofrecerá una presentación el 4 de marzo de 2025, a las 11:50 a.m. EST. Las partes interesadas pueden acceder a una transmisión en vivo de la presentación a través de la sección 'Eventos y Presentaciones' en la página de Inversores de Annexon. La grabación de la presentación estará disponible en el sitio web de la compañía durante 30 días después.
Annexon Biosciences (Nasdaq: ANNX), 고전적 보체 매개 신경 염증 질환을 위한 새로운 치료법 개발에 주력하는 생명공학 회사가 TD Cowen 제45회 연례 건강 관리 회의에 참여한다고 발표했습니다.
회사의 회장 겸 CEO인 더글라스 러브가 2025년 3월 4일 오전 11시 50분 EST에 발표를 진행할 예정입니다. 관심 있는 분들은 Annexon의 투자자 페이지 '이벤트 및 발표' 섹션을 통해 발표의 실시간 웹캐스트에 접속할 수 있습니다. 발표 녹화는 이후 30일 동안 회사 웹사이트에서 이용 가능합니다.
Annexon Biosciences (Nasdaq: ANNX), une entreprise biopharmaceutique axée sur le développement de nouvelles thérapies pour les maladies neuroinflammatoires médiées par le complément classique, a annoncé sa participation à la 45e Conférence Annuelle sur la Santé de TD Cowen.
Le président et PDG de l'entreprise, Douglas Love, fera une présentation le 4 mars 2025 à 11h50 EST. Les parties intéressées peuvent accéder à un webinaire en direct de la présentation via la section 'Événements et Présentations' sur la page des Investisseurs d'Annexon. L'enregistrement de la présentation sera disponible sur le site web de l'entreprise pendant 30 jours après.
Annexon Biosciences (Nasdaq: ANNX), ein biopharmazeutisches Unternehmen, das sich auf die Entwicklung neuer Therapien für klassisch komplementär vermittelte neuroinflammatorische Erkrankungen konzentriert, hat seine Teilnahme an der 45. jährlichen Gesundheitskonferenz von TD Cowen bekannt gegeben.
Der Präsident und CEO des Unternehmens, Douglas Love, wird am 4. März 2025 um 11:50 Uhr EST eine Präsentation halten. Interessierte können über den Bereich 'Veranstaltungen & Präsentationen' auf der Investoren-Seite von Annexon auf einen Live-Stream der Präsentation zugreifen. Die Aufzeichnung der Präsentation wird für 30 Tage auf der Website des Unternehmens verfügbar sein.
- None.
- None.
BRISBANE, Calif., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical complement-mediated neuroinflammatory diseases of the body, brain, and eye, today announced that Douglas Love, president and chief executive officer, will present at the TD Cowen 45th Annual Health Care Conference on Tuesday, March 4, 2025 at 11:50 a.m. EST.
A live webcast of the event can be accessed under the ‘Events & Presentations’ section on the Investors page at www.annexonbio.com. A replay of the webcast will be archived on the Annexon website for 30 days following the presentation.
About Annexon
Annexon Biosciences (Nasdaq: ANNX) is developing therapeutics that stop classical complement-driven neurodegeneration as first-in-kind treatments for millions of people living with serious neuroinflammatory diseases of the body, brain and eye. Our novel scientific approach focuses on C1q, the initiating molecule of classical complement’s potent inflammatory pathway that when misdirected can lead to tissue damage and loss. By targeting C1q, our immunotherapies are designed to stop this neuroinflammatory cascade in disease before it starts. Our pipeline spans three diverse therapeutic areas – autoimmune, neurodegenerative and ophthalmic diseases – and includes targeted investigational drug candidates designed to address the unmet needs of over 8 million people worldwide. Annexon’s mission is to deliver game-changing therapies to patients so that they can live their best lives. To learn more visit annexonbio.com.
Investor Contact:
Joyce Allaire
LifeSci Advisors
jallaire@lifesciadvisors.com
Media Contact:
Sheryl Seapy
Real Chemistry
949-903-4750
sseapy@realchemistry.com
FAQ
When is Annexon Biosciences (ANNX) presenting at the TD Cowen Healthcare Conference 2025?
How can investors watch Annexon's (ANNX) TD Cowen conference presentation?
How long will Annexon's (ANNX) TD Cowen conference presentation be available for replay?
What type of diseases does Annexon Biosciences (ANNX) focus on treating?
